Invesco Dynamic Biotechnology & Genome ETF (PBE)

NYSEARCA: PBE · IEX Real-Time Price · USD
+0.68 (1.03%)
Aug 15, 2022 3:59 PM EDT - Market closed
Assets $260.76M
NAV $65.35
Expense Ratio 0.59%
PE Ratio 25.59
Shares Out 3.99M
Dividend (ttm) n/a
Dividend Yield n/a
Ex-Dividend Date n/a
1-Year Return -12.12%
Volume 6,745
Open 66.00
Previous Close 66.02
Day's Range 66.00 - 66.77
52-Week Low 51.39
52-Week High 79.92
Beta 0.94
Holdings 32
Inception Date Jun 23, 2005

About PBE

The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Asset Class Equity
Sector Biotech
Region North America
Issuer Invesco
Stock Exchange NYSEARCA
Ticker Symbol PBE
Index Tracked Dynamic Biotechnology & Genome Intellidex Index

Top 10 Holdings

44.29% of assets
Name Symbol Weight
ChemoCentryx CCXI 5.44%
Catalent CTLT 4.79%
Vertex Pharmaceuticals VRTX 4.62%
Biogen BIIB 4.60%
Bio-Techne TECH 4.48%
Amgen AMGN 4.15%
Incyte INCY 4.15%
Gilead Sciences GILD 4.12%
Enanta Pharmaceuticals ENTA 3.98%
View More Holdings


Ex-Dividend Amount Pay Date
Mar 23, 2020 $0.02898 Mar 31, 2020
Sep 24, 2018 $0.00207 Sep 28, 2018
Jun 16, 2017 $0.21532 Jun 30, 2017
Mar 17, 2017 $0.05552 Mar 31, 2017
Dec 16, 2016 $0.1208 Dec 30, 2016
Sep 16, 2016 $0.02834 Sep 30, 2016
Full Dividend History


A Comprehensive Guide to Genomic ETFs

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE

Pharma & Biotech ETFs at One-Month High: Here's Why

Pharma and biotech ETFs are in great shape and are trading at a one-month high level.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

Biotech ETFs That Outperformed Last Week

Biotech ETFs was the biggest gainer last week.

Healthcare Emerges as Best Sector of Last Week: 5 Top ETFs

Wall Street was downbeat last week with all indexes in the red. Still, Healthcare sector emerged as a key winner last week.


Top ETFs Tracking CRISPR Gene Editing

These ETFs give you exposure to CRISPR gene editing without having to pick individual stocks.


Biotech ETFs Benefit From Moderna Dual Booster Shot News

As the stock market attempts to reverse the recent pullback this month, Moderna shares climbed higher on Thursday after the company announced that it's creating a dual-purpose vaccine booster shot that ...

Other symbols: MRNA

Could Biotech ETFs Get Another Boost From JNJ News?

This has been a pivotal week for biotech news, as Johnson & Johnson said Wednesday that a booster shot of its COVID-19 vaccine generated a promising immune response in early stage clinical trials. This ...

Other symbols: BIB

Biotech ETFs Are Already Benefitting from Pfizer Vaccine's Full Approval

There could be big gains ahead for biotech ETFs, as the Food and Drug Administration on Monday fully approved the Pfizer and BioNTech coronavirus vaccine, making it the first vaccine in the U.S. to be a...

Other symbols: BIB

How Are Genomics ETFs Responding to Q2 Earnings?

Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.

9 Best Biotech ETFs to Play High-Octane Trends

Biotechnology is a dynamic but often volatile industry. These biotech ETFs provide a lower-risk way to invest in the space.

Will Biotech ETFs Benefit from Biogen's New Alzheimer's Drug?

Biotech investors may have reason to celebrate this week, as the FDA approved Biogen's Alzheimer's disease drug Aducanumab on Monday, ushering in the first medication to be allowed by U.S. regulators to...

Other symbols: BBHFBT

Biotech ETFs Surge on Biogen's Alzheimer Drug Approval

The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.


5 Top ETFs With Exposure To Biogen

For the first time in 18 years, there was a new treatment for Alzheimer's Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that can reduce the clinical decli...


Play 3 Emerging ETF Trends to Follow Cathie Wood

Many would like to follow Ark Investment Management founder Cathie Wood's vision due to her success. She says that digital wallets and genomics will be the next two biggest disruptive trends after Tesla...


Biopharma Here to Stay: The Long-Term Case for the PBE ETF

The coronavirus pandemic could be a long-term positive for biopharma companies and the Invesco Dynamic Biotechnology & Genome ETF (PBE). PBE tracks the Dynamic Biotech & Genome Intellidex Index, which “...

A Guide to Biotech ETF Investing Amid the Coronavirus Crisis

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.

ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion

AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.

Other symbols: BBHFBTPJPPPH

3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover

The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexion ...

Other symbols: BBHFBT

2 Biotech Funds Poised for a Healthy Breakout

Biotech stocks are likely to remain in focus through year end amid news surrounding COVID-19 vaccines and treatments.

Other symbols: IBB

Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?

Sector ETF report for PBE

ETFs That Gained the Most in One of Best Post-Election Rallies

Wall Street booked remarkable gains a day after the election on hopes of a divided Congress.


Biotech ETFs to Shine on Coronavirus Antibodies Progress

With Regeneron Pharmaceuticals and Eli Lilly & Company requesting the FDA for an Emergency Use Authorization for their antibody therapy treatments, the biotech space is filled with optimism.

Other symbols: ARKGBBHIBBXBI

Genomics ETFs Surge on Nobel Prize for Gene-Editing Pioneers

The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.

Other symbols: ARKGGNOMIDNA